The risk for cardiovascular disease in women: From estrogens to selective estrogen receptor modulators

Frontiers in Bioscience

Volumn 12, Issue 1, 2007, Pages 49-68

  Cano, Antonio ^a,c   Hermenegildo, Carlos ^b   Oviedo, Pilar ^a   Tarín, Juan J ^a  

^a UNIVERSITY OF VALENCIA   (Spain)

^b HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^c UNIVERSITY OF VALENCIA   (Spain)

Author keywords

Cardiovascular disease; Coronary heart disease; Review; SERMs; Stroke; Venous thromboembolic Disease; Women

Indexed keywords

EID: 34249788431     PISSN: 27686701     EISSN: 27686698     Source Type: Journal    
DOI: 10.2741/2048     Document Type: Article

References (203)

1. American Heart Association (http://www.americanheart.org)
2. European Cardiovascular Disease Statistics. 2000 edition. British Heart Foundation
3. World Health Organization Web site www.who.int/ncd/cvd.
4. White RH: The epidemiology of venous thromboembolism. Circulation. 107(23 Suppl 1), I 4-8 (2003)
5. Wenger NK: You've come a long way, baby: cardiovascular health and disease in women: problems and prospects. Circulation. 109,558-560 (2004)
6. http://cne.isciii.es/
7. rd: Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch Intern Med 158, 585-593 (1998)
8. Romero A, Alonso C, Rincon M, Medrano J, Santos JM, Calderon E, Marin I, Gonzalez MA: Risk of venous thromboembolic disease in women A qualitative systematic review. Eur J Obstet Gynecol Reprod Biol 121, 8-17 (2005)
9. Bhavnani BR, Strickler RC: Menopausal hormone therapy. J Obstet Gynaecol Can.21, 137-162 (2005)
10. http://www.nhlbi.nih.gov/about/framingham
11. Kannel WB, Hjortland MC, McNamara PM, Gordon T: Menopause and risk of cardiovascular disease: the Framingham study. Ann Intern Med. 85: 447-452 (1976)
12. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, Vittinghoff E: Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 280, 605-613 (1998)
13. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J; Writing Group for the Women's Health Initiative Investigators: Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 288, 321-333 (2002)
14. Anderson GL, Limacher M, Assaf AR, Bassford T, Beresford SA, Black H, Bonds D, Brunner R, Brzyski R, Caan B, Chlebowski R, Curb D, Gass M, Hays J, Heiss G, Hendrix S, Howard BV, Hsia J, Hubbell A, Jackson R, Johnson KC, Judd H, Kotchen JM, Kuller L, LaCroix AZ, Lane D, Langer RD, Lasser N, Lewis CE, Manson J, Margolis K, Ockene J, O'Sullivan MJ, Phillips L, Prentice RL, Ritenbaugh C, Robbins J, Rossouw JE, Sarto G, Stefanick ML, Van Horn L, Wactawski-Wende J, Wallace R, Wassertheil-Smoller S; Women's Health Initiative Steering Committee: Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 291, 1701-1712 (2004)
15. Speroff L: The impact of the Women's Health Initiative on clinical practice. J Soc Gynecol Investig 9, 251-253 (2002)
16. Hall JM, Couse JF, Korach KS: The multifaceted mechanisms of estradiol and estrogen receptor signaling. J Biol Chem 276, 36869-36872 (2001)
17. Mendelsohn ME: Genomic and nongenomic effects of estrogen in the vasculature. Am J Cardiol 90(1A), 3F-6F (2002)
18. Levin ER: Integration of the extranuclear and nuclear actions of estrogen. Mol Endocrinol 19, 1951-1959 (2005)
19. Koehler KF, Helguero LA, Haldosen LA, Warner M, Gustafsson JA: Reflections on the discovery and significance of estrogen receptor beta. Endocr Rev 26, 465-478 (2005)
20. Weihua Z, Andersson S, Cheng G, Simpson ER, Warner M, Gustafsson JA: Update on estrogen signaling. FEBS Lett 546, 17-24 (2003)
21. McDonnell DP: The molecular pharmacology of SERMs. Trends Endocrinol Metab 10, 301-311 (1999)
22. Ross R: Atherosclerosis - an inflammatory disease. N Engl J Med 340, 115-126 (1999)
23. Gibbons GH, Dzau VJ: The emerging concept of vascular remodeling. N Engl J Med 330, 1431-1438 (1994)
24. Hansson GK: Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 352, 1685-1695 (2005)
25. Halcox JP, Schenke WH, Zalos G, Mincemoyer R, Prasad A, Waclawiw MA, Nour KR, Quyyumi AA: Prognostic value of coronary vascular endothelial dysfunction. Circulation 106: 653-658 (2002)
26. Davies MJ: Stability and instability: two faces of coronary atherosclerosis. The Paul Dudley White Lecture 1995. Circulation 94: 2013-2020 (1996)
27. Badimon JJ, Zaman A, Helft G, Fayad Z, Fuster V: Acute coronary syndromes: pathophysiology and preventive priorities. Thromb Haemost 82, 997-1004 (1999)
28. Breslow JL: Mouse models of atherosclerosis. Science 272, 685-688 (1996)
29. Jawien J, Nastalek P, Korbut R: Mouse models of experimental atherosclerosis. J Physiol Pharmacol 55:503-517 (2004)
30. Ohashi R, Mu H, Yao Q, Chen C: Cellular and molecular mechanisms of atherosclerosis with mouse models. Trends Cardiovasc Med 14:187-190 (2004)
31. The Writing Group for the PEPI Trial: Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA 273, 199-208 (1995)
32. Tsimikas S, Brilakis ES, Miller ER, McConnell JP, Lennon RJ, Kornman KS, Witztum JL, Berger PB: Oxidized phospholipids, Lp(a) lipoprotein, and coronary artery disease. N Engl J Med 353, 46-57 (2005)
33. Santanam, N., Shern-Brewer, R., McClatchey, R., Castellano, P.Z., Murphy, A.A., Voelkel, S. and Parthasarathy, S: Estradiol as an antioxidant: incompatible with its physiological concentrations and function. J Lip Res 39, 2111-2118 (1998)
34. Hermenegildo C, García-Martínez MC, Tarín JJ, Llácer A, Cano A: The effect of oral hormone replacement therapy on lipoprotein profile, resistance of LDL to oxidation and LDL particle size. Maturitas 38, 287-295 (2001)
35. Hoogerbrugge N, Zillikens MC, Jansen H, Meeter K, Deckers JW, Birkenhager JC: Estrogen replacement decreases the level of antibodies against oxidized low-density lipoprotein in postmenopausal women with coronary heart disease. Metabolism 47, 675-680 (1998)
36. Heikkinen AM, Niskanen L, Yla-Herttuala S, Luoma J, Tuppurainen MT, Komulainen M, Saarikoski S: Postmenopausal hormone replacement therapy and autoantibodies against oxidized LDL. Maturitas 29, 155-161 (1998)
37. Uint L, Gebara OC, Pinto LB, Wajngarten M, Boschcov P, da Luz PL, Gidlund M: Hormone replacement therapy increases levels of antibodies against heat shock protein 65 and certain species of oxidized low density lipoprotein. Braz J Med Biol Res 36, 491-494 (2003)
38. Liu TZ, Stern A, Morrow JD: The isoprostanes: unique bioactive products of lipid peroxidation. An overview. J Biomed Sci 5, 415-420 (1998)
39. de Zwart LL, Meerman JH, Commandeur JN, Vermeulen NP: Biomarkers of free radical damage applications in experimental animals and in humans. Free Radic Biol Med 26, 202-226 (1999)
40. Pratico D: F(2)-isoprostanes: sensitive and specific non-invasive indices of lipid peroxidation in vivo. Atherosclerosis 147, 1-10 (1999)
41. Gross M, Steffes M, Jacobs DR Jr, Yu X, Lewis L, Lewis CE, Loria CM: Plasma F2-Isoprostanes and Coronary Artery Calcification: The CARDIA Study. Clin Chem 51, 125-131 (2005)
42. Zhang R, Brennan ML, Fu X, Aviles RJ, Pearce GL, Penn MS, Topol EJ, Sprecher DL, Hazen SL: Association between myeloperoxidase levels and risk of coronary artery disease. JAMA 286:2136-2142 (2001)
43. Brennan ML, Penn MS, Van Lente F, Nambi V, Shishehbor MH, Aviles RJ, Goormastic M, Pepoy ML, McErlean ES, Topol EJ, Nissen SE, Hazen SL: Prognostic value of myeloperoxidase in patients with chest pain. N Engl. J Med 349:1595-1604 (2003)
44. Kutter D, Devaquet P, Vanderstocken G, Paulus JM, Marchai V, Gothot A: Consequences of total and subtotal myeloperoxidase deficiency: risk or benefit? Acta Haematol 104:10-15 (2000)
45. Hermenegildo C, Garcia-Martinez MC, Valldecabres C, Tarin JJ, Cano A: Transdermal estradiol reduces plasma myeloperoxidase levels without affecting the LDL resistance to oxidation or the LDL particle size. Menopause 9:102-109 (2002)
46. Makela R, Dastidar P, Jokela H, Saarela M, Punnonen R, Lehtimaki T: Effect of long-term hormone replacement therapy on atherosclerosis progression in postmenopausal women relates to myeloperoxidase promoter polymorphism. J Clin Endocrinol Metab 88:3823-3828 (2003)
47. Karas RH, Patterson BL, Mendelsohn ME: Human vascular smooth muscle cells contain functional estrogen receptor. Circulation 89, 1943-1950 (1994)
48. Venkov C, Rankin A, Vaughan D: Identification of authentic estrogen receptor in cultured endothelial cells: a potential mechanism for steroid hormone regulation of endothelial function. Circulation 94, 727-733 (1996)
49. Jokela H, Dastidar P, Rontu R, Salomaki A, Teisala K, Lehtimaki T, Punnonen R: Effects of long-term estrogen replacement therapy versus combined hormone replacement therapy on nitric oxide-dependent vasomotor function. J Clin Endocrinol Metab 88, 4348-4354 (2003)
50. Sarrel PM: The differential effects of oestrogens and progestins on vascular tone. Hum Reprod Update 5, 205-209 (1999)
51. Todaka T, Yokoyama C, Yanamoto H, Hashimoto N, Nagata I, Tsukahara T, Hara S, Hatae T, Morishita R, Aoki M Ogihara T, Kaneda Y, Tanabe T: Gene transfer of human prostacyclin synthase prevents neointimal formation after carotid balloon injury in rats.Stroke, 30, 419-426 (1999)
52. Niebauer J, Maxwell AJ, Lin PS, Wang D, Tsao PS, Cooke JP: NOS inhibition accelerates atherogenesis: reversal by exercise. Am J Physiol Heart Circ Physiol 285, H535-H540 (2003)
53. Perrault LP, Malo O, Bidouard JP, Villeneuve N, Vilaine JP, Vanhoutte PM: Inhibiting the NO pathway with intiacoronary L-NAME infusion increases endothelial dysfunction and intimai hyperplasia after heart transplantation. J Heart Lung Transplant 22, 439-451 (2003)
54. Hwang J, Mack WJ, Xiang M, Sevanian A, Lobo RA, Hodis HN: Long-term effect of eslrogen replacement on plasma nitric oxide levels: results from the estrogen in the prevention of atherosclerosis trial (EPAT) A therosclerosis 181, 375-380 (2005)
55. Fulimoto J, Sakaguchi H, Hirose R, Tamaya T: Sex steroidal regulation of vessel permeability associated with vessel endothelial cadherin (v-cadherin) J Steroid Biochem Mol Biol 67:25-32 (1998)
56. Bobryshev YV, Cherian SM, Inder SJ, Lord RSA: Neovascular expression of VE-cadherin in human atherosclerotic arteries in its relation to intimal inflammation. Cardiovasc Res 43: 1003-1017 (1999)
57. Hwang SJ, Ballantyne CM, Sharrett AR, Smith LC, Davis CE, Gotto AM Jr, Boerwinkle E: Circulating adhesion molecules VCAM-1, ICAM-1, and E-selectin in carotid atherosclerosis and incident coronary heart disease cases: the Atherosclerosis Risk In Communities (ARIC) study. Circulation 96:4219-4225 (1997)
58. Blankenberg S, Rupprecht HJ, Bickel C, Peetz D, Hafner G, Tiret L, Meyer J: Circulating cell adhesion molecules and death in patients with coronary artery disease. Circulation 104:1336-1342 (2001)
59. Wakatsuki A, Ikenoue N, Shinohara K, Watanabe K, Fukaya T: Effect of lower dosage of oral conjugated equine estrogen on inflammatory markers and endothelial function in healthy postmenopausal women. Arteriosder Thromb Vasc Biol 24:571-576 (2004)
60. Koh KK, Blum A, Hathaway L, Mincemoyer R, Csako G, Waclawiw MA, Panza JA, Cannon RO 3rd: Vascular effects of estrogen and vitamin E therapies in postmenopausal women, Circulation 100:1851-1857 (1999)
61. Koh KK, Bui MN, Mincemoyer R, Cannon RO 3rd: Effects of hormone therapy on inflammatory cell adhesion molecules in postmenopausal healthy women. Am J Cardiol 80:1505-1507 (1997)
62. Moraghan T, Antoniucci DM, Grenert JP, Sieck GC, Johnson C, Miller VM, Fitzpatrick LA Differential response in cell proliferation to beta estradiol in coronary arterial vascular smooth muscle cells obtained from mature female versus male animals. Endocrinology 137, 5174-5177 (1996)
63. Espinosa E, Oemar BS, Luscher TF: 17 beta-Estradiol and smooth muscle cell proliferation in aortic cells of male and female rats. Biochem Biophys Res Commun 221, 8-14 (1996)
64. Bhalla RC, Toth KF, Bhatty RA, Thompson LP, Sharma RV: Estrogen reduces proliferation and agonist-induced calcium increase in coronary artery smooth muscle cells. Am J Physiol 272, H1996-H2003 (1997)
65. Akishita M, Ouchi Y, Miyoshi H, Kozaki K, Inoue S, Ishikawa M, Eto M, Toba K, Orimo H: Estrogen inhibits cuff-induced intimal thickening of rat femoral artery: effects on migration and proliferation of vascular smooth muscle cells. Atherosclerosis 130, 1-10 (1997)
66. Vargas R, Hewes B, Rego A, Farhat MY, Suarez R, Ramwell PW: Estradiol effect on rate of proliferation of rat carotid segments: effect of gender and tamoxifen. J Cardiovasc Pharmacol 27, 495-499 (1996)
67. Ricciardelli C, Horsfall DJ, Sykes PJ, Marshall VR, Tilley WD: Effects of oestradiol-17 beta and 5 alpha-dihydrotestosterone on guinea-pig prostate smooth muscle cell proliferation and steroid receptor expression in vitro. J Endocrinol 140, 373-383 (1994)
68. Song J, Wan Y, Rolfe BE, Campbell JH, Campbell GR: Effect of estrogen on vascular smooth muscle cells is dependent upon cellular phenotype. Atherosclerosis 140, 97-104 (1998)
69. Albert MA: The role of C-reactive protein in cardiovascular disease risk. Curr Cardiol Rep 2: 274-279 (2000)
70. Ridker PM: High-sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. Circulation 103: 1813-1818 (2001)
71. Decensi A, Omodei U, Robertson C, Bonanni B, Guerrieri-Gonzaga A, Ramazzotto F, Johansson H, Mora S, Sandri MT, Cazzaniga M, Franchi M, Pecorelli S: Effect of transdermal estradiol and oral conjugated estrogen on C-reactive protein in retinoid-placebo trial in healthy women. Circulation 106:1224-1228 (2002)
72. Charo IF, Taubman MB: Chemokines in the pathogenesis of vascular disease. Circ Res 95: 858-866 (2004)
73. Hough JL, Zilversmit DB: Effect of 17 beta estradiol on aortic cholesterol content and metabolism in cholesterol-fed rabbits. Arteriosclerosis 6, 57-63 (1986)
74. Haarbo J, Leth-Espensen P, Stender S, Christiansen C: Estrogen monotherapy and combined estrogen-progestogen replacement therapy attenuate aortic accumulation of cholesterol in ovariectomized cholesterol-fed rabbits. J Clin Invest 87, 1274-1279 (1991)
75. Bjarnason NH, Haarbo J, Byrjalsen I, Kauffman RF, Christiansen C: Raloxifene inhibits aortic accumulation of cholesterol in ovariectomized, cholesterol-fed rabbits. Circulation 96, 1964-1969 (1997)
76. Haines CJ, James AE, Panesar NS, Ngai TJ, Sahota DS, Jones RL, Chang AM: The effect of percutaneous oestradiol on atheroma formation in ovariectomized cholesterol-fed rabbits. Atherosclerosis 143, 369-375 (1999)
77. Bjarnason NH, Haarbo J, Byrjalsen I, Alexandersen P, Kauffman RF, Christiansen C: Raloxifene and estrogen reduces progression of advanced atherosclerosis - a study in ovariectomized, cholesterol-fed rabbits. Atherosclerosis 154, 97-102 (2001)
78. Adams MR, Kaplan JR, Manuck SB, Koritnik DR, Parks JS, Wolfe MS, Clarkson TB: Inhibition of coronary artery atherosclerosis by 17-beta estradiol in ovariectomized monkeys. Lack of an effect of added progesterone. Arteriosclerosis 10, 1051-1057 (1990)
79. Wagner JD, Clarkson TB, St Clair RW, Schwenke DC, Shivery CA, Adams MR: Estrogen and progesterone replacement therapy reduces low density lipoprotein accumulation in the coronary arteries of surgically postmenopausal cynomolgus monkeys. J Clin Invest 88, 1995-2002 (1991)
80. Clarkson TB: Estrogens, progestins, and coronary heart disease in cynomolgus monkeys. Fertil Steril 62(Suppl 2), 147S-151S (1994)
81. Herrington DM, Reboussin DM, Brosnihan KB, Sharp PC, Shumaker SA, Snyder TE, Furberg CD, Kowalchuk GJ, Stuckey TD, Rogers WJ, Givens DH, Waters D: Effects of estrogen replacement on the progression of coronary-artery atherosclerosis. N Engl J Med 343, 522-529 (2000)
82. Waters DD, Alderman EL, Hsia J, Howard BV, Cobb FR, Rogers WJ, Ouyang P, Thompson P, Tardif JC, Higginson L, Bittner V, Steffes M, Gordon DJ, Proschan M, Younes N, Verter JI: Effects of hormone replacement therapy and antioxidant vilamin supplements on coronary atherosclerosis in postmenopausal women: a randomized controlled trial. JAMA 288, 2432-2440 (2002)
83. Hodis HN, Mack WJ, Azen SP, Lobo RA, Shoupe D, Mahrer PR, Faxon DP, Cashin-Hemphill L, Sanmarco ME, French WJ, Shook TL, Gaarder TD, Mehra AO, Rabbani R, Sevanian A, Shil AB, Torres M, Vogelbach KH, Selzer RH; Women's Estrogen-Progestin Lipid-Lowering Hormone Atherosclerosis Regression Trial Research Group: Hormone therapy and the progression of coronary-artery atherosclerosis in postmenopausal women. N Engl J Med 349, 535-545 (2003)
84. Akhrass F, Evans AT, Wang Y, Rich S, Kannan CR, Fogelfeld L, Mazzone T: Hormone replacement therapy is associated with less coronary atherosclerosis in postmenopausal women. J Clin Endocrinol Metab 88, 5611-5614 (2003)
85. Wagner JD, Clarkson TB: The applicability of hormonal effects on atherosclerosis in animals to heart disease in postmenopausal women. Semin Reprod Med 23, 149-156 (2005)
86. Armamento-Villareal R, Sheikh S, Nawaz A, Napoli N, Mueller C, Halstead LR, Brodt MD, Silva MJ, Galbiati E, Caruso PL, Civelli M, Civitelli R: A new selective estrogen receptor modulator, CHF 4227.01, preserves bone mass and microarchitecture in ovariectomized rats. J Bone Miner Res 20: 2178-2188 (2005)
87. Ke HZ, Qi H, Chidsey-Frink KL, Crawford DT, Thompson DD: Lasofoxifene (CP-336,156) protects against the age-related changes in bone mass, bone strength, and total serum cholesterol in intact aged male rats. J Bone Miner Res 16:765-773 (2001)
88. Ke HZ, Qi H, Crawford DT, Chidsey-Frink KL, Simmons HA, Thompson DD: Lasofoxifene (CP-336,156), a selective estrogen receptor modulator, prevents bone loss induced by aging and orchidectomy in the adult rat. Endocrinology 141: 1338-1344 (2000)
89. Ma YL, Bryant HU, Zeng Q, Palkowitz A, Jee WS, Turner CH, Sato M: Long-term dosing of arzoxifene lowers cholesterol, reduces bone turnover, and preserves bone quality in ovariectomized rats. J Bone Miner Res 17: 2256-2264 (2002)
90. Sato M, Turner CH, Wang T, Adrian MD, Rowley E, Bryant HU: LY353381.HCl: a novel raloxifene analog with improved SERM potency and efficacy in vivo. J Pharmacol Exp Ther 287:1-7 (1998)
91. Zuckerman SH, Bryan N: Inhibition of LDL oxidation and myeloperoxidase dependent tyrosyl radical formation by the selective estrogen receptor modulator raloxifene (LY139481 HCL)Atherosclerosis 126: 65-75 (1996)
92. Arteaga E, Villaseca P, Bianchi M, Rojas A, Marshall G: Raloxifene is a better antioxidant of low-density lipoprotein than estradiol or tamoxifen in postmenopausal women in vitro. Menopause 10:142-146 (2003)
93. Hermenegildo C, Garcia-Martinez MC, Tarin JJ, Cano A: Inhibition of low-density lipoprotein oxidation by the pure antiestrogens ICI 182780 and EM-652 (SCH 57068) Menopause 9: 430-435 (2002)
94. Baumer AT, Wassmann S, Ahlbory K, Strehlow K, Muller C, Sauer H, Bohm M, Nickenig G: Reduction of oxidative stress and AT1 receptor expression by the selective oestrogen receptor modulator idoxifene Br J Pharmacol. 134:579-584 (2001)
95. Saarto T, Blomqvist C, Ehnholm C, Taskinen MR, Elomaa I: Antiatherogenic effects of adjuvant antiestrogens: a randomized trial comparing the effects of tamoxifen and toremifene on plasma lipid levels in postmenopausal women with node-positive breast cancer. J Clin Oncol 14, 429-433 (1996)
96. Delmas PD, Bjarnason NH, Mitlak BH, Ravoux AC, Shah AS, Huster WJ, Draper M, Christiansen C: Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med 337, 1641-1647 (1997)
97. Walsh BW, Kuller LH, Wild RA, Paul S, Farmer M, Lawrence JB, Shah AS, Anderson PW: Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women. JAMA 279, 1445-1451 (1998)
98. Herrington DM, Pusser BE, Riley WA, Thuren TY, Brosnihan KB, Brinton EA, MacLean DB: Cardiovascular effects of droloxifene, a new selective estrogen receptor modulator, in healthy postmenopausal women. Arterioscler Thromb Vasc Biol 20, 1606-1612 (2000)
99. Joensuu H, Holli K, Oksanen H, Valavaara R: Serum lipid levels during and after adjuvant toremifene or tamoxifen therapy for breast cancer. Breast Cancer Res Treat 63, 225-234 (2000)
100. Decensi A, Robertson C, Viale G, Pigatto F, Johansson H, Kisanga ER, Veronesi P,Torrisi R, Cazzaniga M, Mora S, Sandri MT, Pelosi G, Luini A, Goldhirsch A, Lien EA, Veronesi U: A randomized trial of low-dose tamoxifen on breast cancer proliferation and blood estrogenic biomarkers. J Natl Cancer Inst 95, 779-790 (2003)
101. Mosca L, Barrett-Connor E, Wenger NK, Collins P, Grady D, Kornitzer M, Moscarelli E, Paul S, Wright TJ, Helterbrand JD, Anderson PW: Design and methods of the Raloxifene Use for The Heart (RUTH) study. Am J Cardio. 88:392-395 (2001)
102. Reid IR, Eastell R, Fogelman I, Adachi JD, Rosen A, Netelenbos C, Watts NB, Seeman E, Ciaccia AV, Draper MW: A comparison of the effects of raloxifene and conjugated equine estrogen on bone and lipids in healthy postmenopausal women. Arch Intern Med 164:871-879 (2004)
103. Hozumi Y, Kawano M, Miyata M: Severe hypertriglyceridemia caused by tamoxifen-treatment after breast cancer surgery. Endocr J 44:745-749 (1997)
104. Kanel KT, Wolmark N, Thompson PD: Delayed severe hypertriglyceridemia from tamoxifen. N Engl J Med 337:281 (1997)
105. Ylikorkala O, Cacciatore B, Halonen K, Lassila R, Lammintausta R, Rutanen EM, Heikkinen J, Komi J: Effects of ospemifene, a novel SERM, on vascular markers and function in healthy, postmenopausal women. Menopause 10: 440-447 (2003)
106. Vogelvang TE, Mijatovic V, Kenemans P, Teerlink T, van der Mooren MJ: HMR 3339, a novel selective estrogen receptor modulator, reduces total cholesterol, low-density lipoprotein cholesterol, and homocysteine in healthy postmenopausal women. Fertil Steril 82:1540-1549 (2004)
107. 2α-isoprostane levels in postmenopausal women. Fertil Steril 84:1789-1792 (2005)
108. Barrett-Connor E, Grady D, Sashegyi A, Anderson PW, Cox DA, Hoszowski K, Rautaharju P, Harper KD; MORE Investigators (Multiple Outcomes of Raloxifene Evaluation): Raloxifene and cardiovascular events in osteoporotic postmenopausal women: four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial. JAMA 287:847-857 (2002)
109. Simoncini T, Genazzani AR, Liao JK: Nongenomic mechanisms of endothelial nitric oxide synthase activation by the selective estrogen receptor modulator raloxifene. Circulation 105:1368-1373 (2002)
110. Wassmann S, Laufs U, Stamenkovic D, Linz W, Stasch JP, Ahlbory K, Rosen R, Bohm M, Nickenig G: Raloxifene improves endothelial dysfunction in hypertension by reduced oxidative stress and enhanced nitric oxide production. Circulation 105: 2083-2091 (2002)
111. Oviedo PJ, Hermenegildo C, Cano A: Raloxifene increases the capacity of serum to promote prostacyclin release in human endothelial cells: implication of COX-1 and COX-2. Menopause 11: 430-437 (2004)
112. Oviedo PJ, Hermenegildo C, Tarin JJ, Cano A: Raloxifene promotes prostacyclin release in human endothelial cells through a mechanism that involves cyclooxygenase-1 and -2. Fertil Steril 83:1822-1829 (2005)
113. Rahimian R, Dube GP, Toma W, Dos Santos N, McManus BM, van Breemen C: Raloxifene enhances nitric oxide release in rat aorta via increasing endothelial nitric oxide mRNA expression. Eur J Pharmacol 434: 141-149 (2002)
114. Hutchison SJ, Chou TM, Chatterjee K, Sudhir K: Tamoxifen is an acute, estrogen-like, coronary vasodilator of porcine coronary arteries in vitro. J Cardiovasc Pharmacol 38:657-665 (2001)
115. Zoma WD, Baker RS, Clark KE. Coronary and uterine vascular responses to raloxifene in the sheep. Am J Obstet Gynecol 182:521-528 (2000)
116. Figtree GA, Webb CM, Collins P: Tamoxifen acutely relaxes coronary arteries by an endothelium-, nitric oxide-, and estrogen receptor-dependent mechanism J Pharmacol Exp Ther 295:519-523 (2000)
117. Christopher TA, Lopez BL, Stillwagon JC, Gao F, Gao E, Ma XL, Ohlstein EH, Vue TL: Idoxifene causes endothelium-dependent, nitric oxide-mediated vasorelaxation in male rats. Eur J Pharmacol 446:139-143 (2002)
118. Gonzalez-Perez J, Crespo MJ: Chronic effects of toremifene on the vasculature of menopause-induced rats. Vascul Pharmacol 40:261-268 (2003)
119. Thorin E, Pham-Dang M, Clement R, Mercier I, Calderone A: Hyper-reactivity of cerebral arteries from ovariectomized rats: therapeutic benefit of tamoxifen.Br J Pharmacol 140:1187-1192 (2003)
120. Tatchum-Talom R, Martel C, Labrie F, Marette A: Acute vascular effects of the selective estrogen receptor modulator EM-652 (SCH 57068) in the rat mesenteric vascular bed. Cardiovasc Res 57:535-543 (2003)
121. Sarrel PM, Nawaz H, Chan W, Fuchs M, Katz DL: Raloxifene and endothelial function in healthy postmenopausal women. Am J Obstet Gynecol 188: 304-309 (2003)
122. Saitta A, Altavilla D, Cucinotta D, Morabito N, Frisina N, Corrado F, D'Anna R, Lasco A, Squadrito G, Gaudio A, Cancellieri F, Arcoraci V, Squadrito F: Randomized, double-blind, placebo-controlled study on effects of raloxifene and hormone replacement therapy on plasma NO concentrations, endothelin-1 levels, and endothelium-dependent vasodilation in postmenopausal women. Arterioscler Thromb Vasc Biol 21:1512-1519 (2001)
123. Colacurci N, Manzella D, Fornaro F, Carbonella M, Paolisso G: Endothelial function and menopause: effects of raloxifene administration. J Clin Endocrinol Metab 88:2135-2140 (2003)
124. Ceresini G, Marchini L, Rebecchi I, Morganti S, Bertone L, Montanari I, Bacchi-Modena A, Sgarabotto M, Baldini M, Denti L, Ablondi F, Ceda GP, Valenti G: Effects of raloxifene on carotid blood flow resistance and endothelium-dependent vasodilation in postmenopausal women. Atherosclerosis 167:121-127 (2003)
125. Griffiths KA, Sader MA, Skilton MR, Harmer JA, Celermajer DS: Effects of raloxifene on endothelium-dependent dilation, lipoproteins, and markers of vascular function in postmenopausal women with coronary artery disease. J Am Coll Cardiol 42:698-704 (2003)
126. rd: Effects of estrogen and the selective estrogen receptor modulator raloxifene on markers of inflammation in postmenopausal women. Am J Cardiol 86:892-895 (2000)
127. Sbarouni E, Flevari P, Kroupis C, Kyriakides ZS, Koniavitou K, Kremastinos DT: The effects of raloxifene and simvastatin on plasma lipids and endothelium. Cardiovasc Drugs Ther 17:319-323 (2003)
128. Simoncini T, De Caterina R, Genazzani AR. Selective estrogen receptor modulators: different actions on vascular cell adhesion molecule-1 (VCAM-1) expression in human endothelial cells. J Clin Endocrinol Metab 84:815-818 (1999)
129. Herrington DM, Brosnihan KB, Pusser BE, Seely EW, Ridker PM, Rifai N, MacLean DB: Differential effects of E and droloxifene on C-reactive protein and other markers of inflammation in healthy postmenopausal women. J Clin Endocrinol Metab 86:4216-4222 (2001)
130. Seli E, Pehlivan T, Selam B, Garcia-Velasco JA, Arici A: Estradiol down-regulates MCP-1 expression in human coronary artery endothelial cells. Fertil Steril 77:542-547 (2002)
131. Takahashi K, Ohmichi M, Yoshida M, Hisamoto K, Mabuchi S, Arimoto-Ishida E, Mon A, Tsutsumi S, Tasaka K, Murata Y, Kurachi H: Both estrogen and raloxifene cause G1 arrest of vascular smooth muscle cells. J Endocrinol 178:319-329 (2003)
132. Mon-Abe A, Tsutsumi S, Takahashi K, Toya M, Yoshida M, Du B, Kawagoe J, Nakahara K, Takahashi T, Ohmichi M, Kurachi H: Estrogen and raloxifene induce apoptosis by activating p38 mitogen-activated protein kinase cascade in synthetic vascular smooth muscle cells. J Endocrinol 178:417-426 (2003)
133. Selzman CH, Tumer AS, Gaynor JS, Miller SA, Monnet E, Harken AH: Inhibition of intimal hyperplasia using the selective estrogen receptor modulator raloxifene. Arch Surg 137:333-336 (2002)
134. Grainger DJ, Weissberg PL, MeteaKe JC: Tamoxifen decreases the rate of proliferation of rat vascular smooth-muscle cells in culture by inducing production of transforming growth factor beta. Biochem J 294: 109-112 (1993)
135. Somjen D, Kohen F, Jaffe A, Amir-Zaltsman Y, Knoll E, Stern N: Effects of gonadal steroids and their antagonists on DNA synthesis in human vascular cells. Hypertension 32: 39-45 (1998)
136. Dubey RK, Tyurina YY, Tyurin VA, Gillespie DG, Branch RA, Jackson EK, Kagan VE: Estrogen and tamoxifen metabolites protect smooth muscle cell membrane phospholipids against peroxidation and inhibit cell growth. Circ Res 84:229-239 (1999)
137. Yue TL, Vickery-Clark L, Louden CS, Gu JL, Ma XL, Narayanan PK, Li X, Chen J, Storer B, Willette R, Gossett KA, Ohlstein EH: Selective estrogen receptor modulator idoxifene inhibits smooth muscle cell proliferation, enhances reendothelialization, and inhibits neointimal formation in vivo after vascular injury. Circulation 102(Suppl 3):III281-III288 (2000)
138. Reckless J, Metcalfe JC, Grainger DJ: Tamoxifen decreases cholesterol sevenfold and abolishes lipid lesion development in apolipoprotein E knockout mice. Circulation 95: 1542-1548 (1997)
139. Bjarnason NH, Haarbo J, Byrjalsen I, Kauffman RF, Knadler MP, Christiansen C: Raloxifene reduces atherosclerosis: studies of optimized raloxifene doses in ovariectomized, cholesterol-fed rabbits. Clin Endocrinol (Oxf) 52:225-233 (2000)
140. Clarkson TB, Anthony MS, Jerome CP: Lack of effect of raloxifene on coronary artery atherosclerosis of postmenopausal monkeys. J Clin Endocrinol Metab 83:721-726 (1998)
141. Fuster V, Badimon L, Badimon JJ, Chesebro JH: The pathogenesis of coronary artery disease and the acute coronary syndromes (Part 1 of 2) N Eng J Med 326: 242-250 (1992)
142. Fuster V, Badimon L, Badimon JJ, Chesebro JH: The pathogenesis of coronary artery disease and the acute coronary syndromes (Part 2 of 2) N Eng J Med 326: 310-318 (1992)
143. Rader DJ: Inflammatory markers of coronary risk. N Engl J Med 343:1179 (2000)
144. Davison S, Davis SR: New markers for cardiovascular disease risk in women: impact of endogenous estrogen status and exogenous postmenopausal hormone therapy. J Clin Endocrinol Metab 88:2470-2478 (2003)
145. Walsh BW, Paul S, Wild RA, Dean RA, Tracy RP, Cox DA, Anderson PW: The effects of hormone replacement therapy and raloxifene on C-reactive protein and homocysteine in healthy postmenopausal women: a randomized, controlled trial. J Clin Endocrinol Metab 85: 214-218 (2000)
146. Cushman M, Costantino JP, Tracy RP, Song K, Buckley L, Roberts JD, Krag DN: Tamoxifen and cardiac risk factors in healthy women: Suggestion of an anti-inflammatory effect. Arterioscler Thromb Vasc Biol 21:255-261 (2001)
147. Mijatovic V, Netelenbos C, van der Mooren MJ, de Valk-de Roo GW, Jakobs C, Kenemans P: Randomized, double-blind, placebo-controlled study of the effects of raloxifene and conjugated equine estrogen on plasma homocysteine levels in healthy postmenopausal women. Fertil Steril 70:1085-1089 (1998)
148. De Leo V, la Marca A, Morgante G, Lanzetta D, Setacci C, Petraglia F: Randomized control study of the effects of raloxifene on serum lipids and homocysteine in older women. Am J Obstet Gynecol 184: 350-353 (2001)
149. Smolders RG, Vogelvang TE, Mijatovic V, van Baal WM, Neele SJ, Netelenbos JC, Kenemans P, van der Mooren MJ: A 2-year, randomized, comparative, placebo-controlled study on the effects of raloxifene on lipoprotein(a) and homocysteine. Maturitas 41: 105-114 (2002)
150. Walsh BW, Cox DA, Sashegyi A, Dean RA, Tracy RP, Anderson PW: Role of tumor necrosis factor-alpha and interleukin-6 in the effects of hormone replacement therapy and raloxifene on C-reactive protein in postmenopausal women. Am J Cardiol 88:825-828 (2001)
151. Elhage R, Clamens S, Besnard S, Mallat Z, Tedgui A, Arnal J, Maret A, Bayard F: Involvement of interleukin-6 in atherosclerosis but not in the prevention of fatty streak formation by 17beta-estradiol in apolipoprotein E-deficient mice. Atherosclerosis 156:315-320 (2001)
152. Gianni W, Ricci A, Gazzaniga P, Brama M, Pietropaolo M, Votano S, Patane F, Agliano AM, Spera G, Marigliano V, Ammendola S, Agnusdei D, Migliaccio S, Scandurra R: Raloxifene modulates interleukin-6 and tumor necrosis factor-alpha synthesis in vivo: results from a pilot clinical study. J Clin Endocrinol Metab 89: 6097-6099 (2004)
153. Ridker PM, Rifai N, Pfeffer M, Sacks F, Lepage S, Braunwald E: Elevation of tumor necrosis factor-alpha and increased risk of recurrent coronary events after myocardial infarction. Circulation 101: 2149-2153 (2000)
154. García-Martínez MC, Labiós M, Hermenegildo C, Tarín JJ, O'Connor E, Cano A: The effect of hormone replacement therapy on Ca2+ mobilization and P- selectin (CD62P) expression in platelets examined under flow cytometry. Blood Coagul Fibrinolysis 15: 1-8 (2004)
155. Weiss EJ, Bray PF, Tayback M, Schulman SP, Kickler TS, Becker LC, Weiss JL, Gerstenblith G, Goldschmidt-Clermont PJ: A polymorphism of a platelet glycoprotein receptor as an inherited risk factor for coronary thrombosis. N Engl J Med 334:1090-1094 (1996)
156. Boudoulas KD, Cooke GE, Roos CM, Bray PF, Goldschmidt-Clermont PJ: The PIA polymorphism of glycoprotein IIIa functions as a modifier for the effect of estrogen on platelet aggregation. Arch Pathol Lab Med 125:112-115 (2001)
157. Bar J, Tepper R, Fuchs J, Pardo J, Goldberger S, Ovadia J: The effect of estrogen replacement therapy on platelet aggregation and adenosine triphosphate release in postmenopausal women. Obstet Gynecol 81: 261-264 (1993)
158. Bar J, Lahav J, Hod M, Ben-Rafael Z, Weinberger I, Brosens J: Regulation of platelet aggregation and adenosine triphosphate release in vitro by 17beta-estradiol and medroxyprogesterone acetate in postmenopausal women. Thromb Haemost 84: 695-700 (2000)
159. Nakano Y, Oshima T, Matsuura H, Kajiyama G, Kambe M: Effect of 17beta-estradiol on inhibition of platelet aggregation in vitro is mediated by an increase in NO synthesis. Arterioscler Thromb Vasc Biol 18: 961-967 (1998)
160. Chen FPL, Lee N, Wang CH, Soong YK: Effects of hormone replacement therapy on cardiovascular risk factors in postmenopausal women. Fertil Steril 69: 267-273 (1998)
161. Jayachandran M, Mukherjee R, Steinkamp T, Labreche P, Bracamonte MP, Okano H, Owen WG, Miller VM: Differential effects of 17 {bete} -estradiol, conjugated equine estrogen and raloxifene on mRNA expression, aggregation and secretion in platelets. Am J Physiol Heart Circ Physiol 288:H2355-H2362 (2005)
162. Miller ME, Dores GM, Thorpe SL, Akerley WL: Paradoxical influence of estrogenic hormones on platelet -endothelial cell interactions. Thromb Res 74:577-594 (1994)
163. Miller ME, Thorpe SL, Dores GM: Influence of hormones on platelet intracellular calcium. Thromb Res 77:515-530 (1995)
164. Cano A, Van Baal WM: The mechanisms of thrombotic risk induced by hormone replacement therapy. Maturitas 40:17-38 (2001)
165. de Valk-de Roo GW, Stehouwer CD, Meijer P, Mijatovic V, Kluft C, Kenemans P, Cohen F, Watts S, Netelenbos C: Both raloxifene and estrogen reduce major cardiovascular risk factors in healthy postmenopausal women: A 2-year, placebo-controlled study. Arterioscler Thromb Vasc Biol 19:2993-3000 (1999)
166. Sanz-Gonzalez SM, Cano A, Valverde MA, Hermenegildo C, Andres V. Drug targeting of estrogen receptor signaling in the cardiovascular system: preclinical and clinical studies. Curr Med Chem Cardiovasc Hematol Agents 2: 107-122 (2004)
167. Duvernoy CS, Kulkarni PM, Dowsett SA, Keech CA: Vascular events in the Multiple Outcomes of Raloxifene Evaluation (MORE) trial: incidence, patient characteristics, and effect of raloxifene. Menopause 12:444-452 (2005)
168. Ensrud K, Riccardo Genazzani A, Geiger MJ, McNabb M, Dowsett SA, Cox DA, Barrett-Connor E. Effect of raloxifene on cardiovascular adverse events in postmenopausal women with osteoporosis. Am J Cardiol 97:520-527 (2006)
169. Reis SE, Costantino JP, Wickerham DL, Tan-Chiu E, Wang J, Kavanah M: Cardiovascular effects of tamoxifen in women with and without heart disease:breast cancer prevention trial. National Surgical Adjuvant Breast and Bowel Project Breast Cancer Prevention Trial Investigators. J Natl Cancer Inst 93:16-21 (2001)
170. Hum PD, Brass LM: Estrogen and stroke: a balanced analysis. Stroke 34:338-341 (2003)
171. Murphy SJ, McCullough LD, Smith JM: Stroke in the female: role of biological sex and estrogen. ILAR J 45:147-159 (2004)
172. rd: Effect of hormone replacement therapy on carotid arterial compliance in healthy postmenopausal women. Am J Cardiol 90:82-85 (2002)
173. Angerer P, Kothny W, Stork S, von Schacky C: Hormone replacement therapy and distensibility of carotid arteries in postmenopausal women: a randomized, controlled trial. J Am Coll Cardiol 36:1789-1796 (2000)
174. Nabulsi AA, Folsom AR, Szklo M, White A, Higgins M, Heiss G: No association of menopause and hormone replacement therapy with carotid artery intima-media thickness. Atherosclerosis Risk in Communities (ARIC) Study Investigators. Circulation 94:1857-1863 (1996)
175. Hodis HN, Mack WJ, Lobo RA, Shoupe D, Sevanian A, Mahrer PR, Selzer RH, Liu Cr CR, Liu Ch CH, Azen SP; Estrogen in the Prevention of Atherosclerosis Trial Research Group: Estrogen in the prevention of atherosclerosis. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 135: 939-953 (2001)
176. Angerer P, Stork S, Kothny W, Schmitt P, von Schacky C: Effect of oral postmenopausal hormone replacement on progression of atherosclerosis: a randomized, controlled trial. Arterioscler Thromb Vasc Biol 21: 262-268 (2001)
177. Paganini-Hill A: Hormone replacement therapy and stroke: risk, protection or no effect? Maturitas 38:243-261 (2001)
178. Viscoli CM, Brass LM, Kernan WN, Sarrel PM, Suissa S, Horwitz RI: A clinical trial of estrogen-replacement therapy after ischemic stroke. N Engl J Med 345:1243-1249 (2001)
179. Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, Vogel V, Robidoux A, Dimitrov N, Atkins J, Daly M, Wieand S, Tan-Chiu E, Ford L, Wolmark N: Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 90:1371-1388 (1998)
180. Dignam JJ, Fisher B: Occurrence of stroke with tamoxifen in NSABP B-24. Lancet 355:848-849 (2000)
181. Braithwaite RS, Chlebowski RT, Lau J, George S, Hess R, Col NF: Meta-analysis of vascular and neoplastic events associated with tamoxifen. J Gen Intern Med 18:937-947 (2003)
182. Bushnell CD, Goldstein LB: Risk of ischemie stroke with tamoxifen treatment for breast cancer: a meta-analysis. Neurology 63:1230-1233 (2004)
183. Geiger AM, Fischberg GM, Chen W, Bernstein L: Stroke risk and tamoxifen therapy for breast cancer. J Natl Cancer Inst 96:1528-1536 (2004)
184. Early Breast Cancer Trialists' Collaborative Group: Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 351:1451-1467 (1998)
185. Harvey HA, Kimura M, Hajba A: Toremifene: An evaluation of its safety profile. Breast. 2005 Nov 8; [Epub ahead of print].
186. Martino S, Cauley JA, Barrett-Connor E, Powles TJ, Mershon J, Disch D, Secrest RJ, Cummings SR; CORE Investigators: Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. J Natl Cancer Inst 96:1751-1761 (2004)
187. Martino S, Disch D, Dowsett SA, Keech CA, Mershon JL: Safety assessment of raloxifene over eight years in a clinical trial setting. Curr Med Res Opin 21: 1441-1452 (2005)
188. Daly E, Vessey MP, Hawkins MM, Carson JL, Gough P, Marsh S: Risk of venous thromboembolism in users of hormone replacement therapy. Lancet 348: 977-980 (1996)
189. Jick H, Derby LE, Myers MW, Vasilakis C, Newton KM: Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal oestrogens. Lancet 348: 981-983 (1996)
190. Grodstein F, Stampfer MJ, Goldhaber SZ, Goldhaber SZ, Manson JE, Colditz GA, Speizer FE, Willett WC, Hennekens CH: Prospective study of exogenous hormones and risk of pulmonary embolism in women. Lancet 348: 983-987 (1996)
191. Pérez- Gutthan S, García-Rodríguez LA, Castellsague J, Duque -Oliart A: Hormone replacement therapy and risk of venous thromboembolism: population based case-control study. BMJ 314: 796-800 (1997)
192. Cuzick J, Powles T, Veronesi U, Forbes J, Edwards R, Ashley S, Boyle P: Overview of the main outcomes in breast-cancer prevention trials. Lancet 361: 296-300 (2003)
193. Delmas PD, Ensrud KE, Adachi JD, Harper KD, Sarkar S, Gennari C, Reginster JY, Pols HA, Recker RR, Harris ST, Wu W, Genant HK, Black DM, Eastell R; Mulitple Outcomes of Raloxifene Evaluation Investigators: Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausalwomen with osteoporosis: four-year results from a randomized clinical trial. J Clin Endocrinol Metab 87:3609-3617 (2002)
194. Cano A. Blood flow and hemostasis. In: Menopause. The State of the Art in research and management. Ed HPG Schneider, Parthenon Publishing, London, 139-145 (2003)
195. Richardson MA, Berg DT, Calnek DS, Ciaccia AV, Joyce DE, Grinnell BW: 17beta-estradiol, but not raloxifene, decreases thrombomodulin in the antithrombotic protein C pathway. Endocrinology 141:3908-3911 (2000)
196. Erman M, Abali H, Oran B, Haznedaroglu IC, Canpinar H, Kirazli S, Celik I: Tamoxifen-induced tissue factor pathway inhibitor reduction: a clue for an acquired thrombophilic state? Ann Oncol 15:1622-1626 (2004)
197. Jones AL, Powles TJ, Treleaven JG, Burman JF, Nicolson MC, Chung HI, Ashley SE: Haemostatic changes and thromboembolic risk during tamoxifen therapy in normal women. Br J Cancer 66:744-747 (1992)
198. Pemberton KD, Melissari E, Kakkar VV: The influence of tamoxifen in vivo on the main natural anticoagulants and fibrinolysis. Blood Coagul Fibrinolysis 4:935-942 (1993)
199. Mannucci PM, Bettega D, Chantarangkul V, Tripodi A, Sacchini V, Veronesi U: Effect of tamoxifen on measurements of hemostasis in healthy women. Arch Intern Med 156:1806-1810 (1996)
200. Cushman M, Costantino JP, Bovill EG, Wickerham DL, Buckley L, Roberts JD, Krag DN: Effect of tamoxifen on venous thrombosis risk factors in women without cancer: the Breast Cancer Prevention Trial. Br J Haematol 120:109-116 (2003)
201. Cosman F, Baz-Hecht M, Cushman M, Vardy MD, Cruz JD, Nieves JW, Zion M, Lindsay R: Short-term effects of estrogen, tamoxifen and raloxifene on henostasis: a randomized-controlled study and review of the literature. Thromb Res 116:1-13 (2005)
202. Ounnoughene N, Molho P, Stieltjes N, Sultan Y: Effect of tamoxifen on von Willebrand factor levels. Arch Intern Med 157:1613 (1997)
203. Duschek EJ, Neele SJ, Thomassen MC, Rosing J, Netelenbos C: Effect of raloxifene on activated protein C (APC) resistance in postmenopausal women and on APC resistance and homocysteine levels in elderly men: two randomized placebo-controlled studies. Blood Coagul Fibrinolysis 15:649-655 (2004)